Case Type: Mergers & Acquisitions

Seneca Biopharma, Inc. (SNCA) relating to its proposed merger with Leading BioSciences, Inc. (“LBS”). Under the terms of the merger agreement, LBS shareholders will be issued Seneca common stock and Seneca shareholders will receive one contingent value right as a dividend for each share they own. Seneca shareholders will only control 26.2% of the combined … Read more

Aerojet Rocketdyne Holdings, Inc. (NYSE: AJRD), relating to its proposed acquisition by L3Harris Technologies, Inc. Under the terms of the agreement, AJRD shareholders are expected to receive $58.00 in cash per share they own.

FinServ Acquisition Corp. (FSRV) relating to its proposed merger with Katapult Holding, Inc. (“Katapult”). Under the terms of the agreement, FinServ will acquire Katapult through a reverse merger that will result in Katapult becoming a publicly traded company.

NantKwest, Inc. (NK) relating to its proposed merger with ImmunityBio. Under the terms of the agreement, ImmunityBio shareholders will receive 0.8190 shares of NatKwest per share they own.

New Providence Acquisition Corp. (NPA) relating to its proposed reverse merger with AST & Science LLC (“AST”). Under the terms of the agreement, NPA will acquire AST through a reverse merger that will result in AST becoming a publicly traded company.

TPG Pace Beneficial Finance Corp. (TPGY) relating to its proposed reverse merger with EV Charged B.V. (“EVBox”). Under the terms of the agreement, TPGY will acquire EVBox through a reverse merger that will result in EVBox becoming a publicly traded company.

BioTelemetry, Inc. (BEAT) relating to its proposed acquisition by Royal Phillips. Under the terms of the agreement, BEAT shareholders will receive $72.00 in cash per share.

TCF Financial Corp. (TCF) relating to its proposed merger with Huntington Bancshares, Inc. Under the terms of the agreement, TCF shareholders will receive 3.0028 shares of Huntington per share they own.

Tottenham Acquisition I Limited (TOTA) relating to its proposed reverse merger with Clene Nanomedicine, Inc. Under the terms of the agreement, Tottenham will acquire Clene through a reverse merger that will result in Clene becoming a publicly traded company.

Prevail Therapeutics, Inc. (PRVL) relating to its proposed acquisition by Eli Lilly and Company. Under the terms of the agreement, Prevail shareholders will receive $22.50 in cash per share, plus one contingent value right, which represents the right to receive a contingent payment of up to $4.00 per share.